Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $34.27, but opened at $33.01. Otsuka shares last traded at $34.55, with a volume of 2,499 shares.
Wall Street Analysts Forecast Growth
OTSKY has been the topic of several research analyst reports. Morgan Stanley raised shares of Otsuka to an "overweight" rating in a report on Friday, January 23rd. UBS Group raised Otsuka to a "hold" rating in a research note on Tuesday, January 27th. The Goldman Sachs Group cut Otsuka from a "strong-buy" rating to a "strong sell" rating in a research report on Friday, February 27th. Finally, Zacks Research lowered Otsuka from a "hold" rating to a "strong sell" rating in a research note on Monday, March 2nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce".
Check Out Our Latest Research Report on Otsuka
Otsuka Trading Up 1.1%
The stock's 50 day simple moving average is $31.22 and its 200 day simple moving average is $29.04. The firm has a market cap of $37.23 billion and a PE ratio of 15.07. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17.
About Otsuka
(
Get Free Report)
Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm's core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.
Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Otsuka, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Otsuka wasn't on the list.
While Otsuka currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.